Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Overview[ - collapse ][ - ]
| Purpose | The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a white blood cell stimulating growth factor. |
|---|---|
| Condition | Breast Cancer |
| Intervention | Drug: Abraxane |
| Phase | N/A |
| Sponsor | Harold J. Burstein, MD, PhD |
| Responsible Party | Dana-Farber Cancer Institute |
| ClinicalTrials.gov Identifier | NCT00308178 |
| First Received | March 28, 2006 |
| Last Updated | February 15, 2013 |
| Last verified | February 2013 |
Tracking Information[ + expand ][ + ]
| First Received Date | March 28, 2006 |
|---|---|
| Last Updated Date | February 15, 2013 |
| Start Date | March 2006 |
| Estimated Primary Completion Date | June 2008 |
| Current Primary Outcome Measures | To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer. [Time Frame: 2 years] [Designated as safety issue: Yes] |
| Current Secondary Outcome Measures |
|
Descriptive Information[ + expand ][ + ]
| Brief Title | Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer |
|---|---|
| Official Title | Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study |
| Brief Summary | The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a white blood cell stimulating growth factor. |
| Detailed Description | - Patients will receive regular chemotherapy every 2 weeks for up to 8 cycles (approximately 16 weeks total)of treatment. During the first four cycles patients will be treated with Adriamycin and Cytoxan, and for the second four cycles they will be treated with Abraxane. - Patients will be taught to give themselves injections with either short or long acting G-CSF as prescribed by their doctor for the first four cycles of chemotherapy. During the last four cycles (while the patient is taking Abraxane) they will not receive G-CSF unless they have low blood counts. - If the patient has HER-2 positive breast cancer, they will also receive 52 weeks of Herceptin as part of standard cancer care and will begin to receive Herceptin at the same time they begin Abraxane (after 4 cycles of adriamycin and cytoxan treatment). - This study involves a series of Quality of Life Questionnaires that will be completed prior to beginning study treatment, then again at 2 months, 4 months, 6 months, and 1 year after starting study treatment. - The following tests and procedures will be performed at the time periods specified. Cycle 1-4 Day 1: Physical exam, vital signs, and blood tests. Cycle 5 Day 1: Physical exam, vital signs, blood tests, RVG (measurement of heart function) and questionnaire. Cycle 6 & 7 Day 1: Physical exam, vital signs, and blood tests. Cycle 8 Day 1: physical exam, vital signs, blood tests, questionnaire. Follow-up (6 months and 1 year after cycle 1 day 1): questionnaire. |
| Study Type | Interventional |
| Study Phase | N/A |
| Study Design | Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Condition | Breast Cancer |
| Intervention | Drug: Abraxane Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks) |
| Study Arm (s) | Not Provided |
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Completed |
|---|---|
| Estimated Enrollment | 66 |
| Estimated Completion Date | June 2008 |
| Estimated Primary Completion Date | September 2006 |
| Eligibility Criteria | Inclusion Criteria: - Histologically or cytologically confirmed breast cancer, with clinical stage I, II, or III disease - Must register at the beginning of adjuvant or neoadjuvant chemotherapy - 18 years of age or older - ECOG performance status of 0 or 1 - Normal organ and marrow function Exclusion Criteria: - Previous cytotoxic chemotherapy or therapeutic radiation therapy for any reason - Pregnant or nursing - Receiving any other investigational agents - Patients with Stage IV breast cancer - Current grade II or greater peripheral neuropathy or prior history of grade II or greater neuropathy - Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Immune deficiency when treated with marrow-suppressive therapy or HIV-positive patients receiving anti-retroviral therapy - Patients with sickle cell disease - Known history of hyperviscosity syndrome - Patients on lithium |
| Gender | Both |
| Ages | 18 Years |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | United States |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT00308178 |
|---|---|
| Other Study ID Numbers | 05-249 |
| Has Data Monitoring Committee | Not Provided |
| Information Provided By | Dana-Farber Cancer Institute |
| Study Sponsor | Harold J. Burstein, MD, PhD |
| Collaborators | Celgene Corporation Beth Israel Deaconess Medical Center Massachusetts General Hospital |
| Investigators | Principal Investigator: Harold Burstein, MD Dana-Farber Cancer Institute |
| Verification Date | February 2013 |
Locations[ + expand ][ + ]
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States, 02115 |
|---|---|
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States, 02215 |
| Massacusetts General Hospital | Boston, Massachusetts, United States, 02114 |